Search Results - "Jose Luis Perez-Gracia"

Evolving synergistic combinations of targeted immunotherapies to combat cancer by Melero, Ignacio, Berman, David M., Aznar, M. Angela, Korman, Alan J., Gracia, José Luis Pérez, Haanen, John

“…Key Points Clinical trials have validated immuno-oncology as a new pillar of anticancer therapy. Combinations could involve two (or more) sequential or…”
Get full text

Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer by Elgendy, Mohamed, Fusco, Juan Pablo, Segura, Victor, Lozano, Maria Dolores, Minucci, Saverio, Echeveste, Jose Ignacio, Gurpide, Alfonso, Andueza, Mapi, Melero, Ignacio, Sanmamed, Miguel F., Ruiz, Maria Rodriguez, Calvo, Alfonso, Pascual, Juan Ignacio, Velis, Jose María, Miñana, Bernardino, Valle, Ricardo Diez, Pio, Ruben, Agorreta, Jackeline, Abengozar, Marta, Colecchia, Maurizio, Brich, Silvia, Renne, Salvatore Lorenzo, Guruceaga, Elisabet, Patiño‐García, Ana, Perez‐Gracia, Jose Luis

“…Sunitinib is one of the most widely used targeted therapeutics for renal cell carcinoma (RCC), but acquired resistance against targeted therapies remains a…”
Get full text

Direct Effects of Type I Interferons on Cells of the Immune System by HERVAS-STUBBS, Sandra, LUIS PEREZ-GRACIA, Jose, ROUZAUT, Ana, SANMAMED, Miguel F, LE BON, Agnes, MELERO, Ignacio

“…Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha…”
Get full text

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis by Datar, Ila, Sanmamed, Miguel F, Wang, Jun, Henick, Brian S, Choi, Jungmin, Badri, Ti, Dong, Weilai, Mani, Nikita, Toki, Maria, Mejías, Luis D, Lozano, Maria D, Perez-Gracia, Jose Luis, Velcheti, Vamsidhar, Hellmann, Matthew D, Gainor, Justin F, McEachern, Kristen, Jenkins, David, Syrigos, Konstantinos, Politi, Katerina, Gettinger, Scott, Rimm, David L, Herbst, Roy S, Melero, Ignacio, Chen, Lieping, Schalper, Kurt A

“…To determine the tumor tissue/cell distribution, functional associations, and clinical significance of PD-1, LAG-3, and TIM-3 protein expression in human…”
Get full text

Orchestrating immune check-point blockade for cancer immunotherapy in combinations by Perez-Gracia, Jose Luis, Labiano, Sara, Rodriguez-Ruiz, Maria E, Sanmamed, Miguel F, Melero, Ignacio

“…Highlights • Immunity against cancer is negatively regulated by lymphocyte surface receptors. • Cellular immunity against cancer can be unleashed by mAbs…”
Get full text

Dual modulation of MCL-1 and mTOR determines the response to sunitinib by Elgendy, Mohamed, Abdel-Aziz, Amal Kamal, Renne, Salvatore Lorenzo, Bornaghi, Viviana, Procopio, Giuseppe, Colecchia, Maurizio, Kanesvaran, Ravindran, Toh, Chee Keong, Bossi, Daniela, Pallavicini, Isabella, Perez-Gracia, Jose Luis, Lozano, Maria Dolores, Giandomenico, Valeria, Mercurio, Ciro, Lanfrancone, Luisa, Fazio, Nicola, Nole, Franco, Teh, Bin Tean, Renne, Giuseppe, Minucci, Saverio

“…Most patients who initially respond to treatment with the multi-tyrosine kinase inhibitor sunitinib eventually relapse. Therefore, developing a deeper…”
Get full text

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens by Perez-Gracia, Jose Luis, Loriot, Yohann, Rosenberg, Jonathan E., Powles, Thomas, Necchi, Andrea, Hussain, Syed A., Morales-Barrera, Rafael, Retz, Margitta M., Niegisch, Günter, Durán, Ignacio, Théodore, Christine, Grande, Enrique, Shen, Xiaodong, Wang, Jingjing, Nelson, Betty, Derleth, Christina L., van der Heijden, Michiel S.

“…Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes…”
Get full text

Cellular cytotoxicity is a form of immunogenic cell death by Minute, Luna, Teijeira, Alvaro, Sanchez-Paulete, Alfonso R, Ochoa, Maria C, Alvarez, Maite, Otano, Itziar, Etxeberrria, Iñaki, Bolaños, Elixabet, Azpilikueta, Arantza, Garasa, Saray, Casares, Noelia, Luis Perez Gracia, Jose, Rodriguez-Ruiz, Maria E, Berraondo, Pedro, Melero, Ignacio

“…BackgroundThe immune response to cancer is often conceptualized with the cancer immunity cycle. An essential step in this interpretation is that antigens…”
Get full text

Assessment of Epidermal Growth Factor Receptor and K‐Ras Mutation Status in Cytological Stained Smears of Non‐Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes by Lozano, Maria D., Zulueta, Javier J., Echeveste, Jose I., Gúrpide, Alfonso, Seijo, Luis M., Martín‐Algarra, Salvador, Barrio, Anabel, Pio, Ruben, Idoate, Miguel Angel, Labiano, Tania, Perez‐Gracia, Jose Luis

“…Objective. Epidermal growth factor receptor (EGFR) and K‐ras mutations guide treatment selection in non‐small cell lung cancer (NSCLC) patients. Although…”
Get full text

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies by Glez-Vaz, Javier, Azpilikueta, Arantza, Olivera, Irene, Cirella, Assunta, Teijeira, Alvaro, Ochoa, Maria C, Alvarez, Maite, Eguren-Santamaria, Iñaki, Luri-Rey, Carlos, Rodriguez-Ruiz, Maria E, Nie, Xinxin, Chen, Lieping, Guedan, Sonia, Sanamed, Miguel F, Perez Gracia, Jose Luis, Melero, Ignacio

“…On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory…”
Get full text

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis by Rodriguez, Javier, Castañón, Eduardo, Perez-Gracia, Jose Luis, Rodriguez, Inmaculada, Viudez, Antonio, Alfaro, Carlos, Oñate, Carmen, Perez, Guiomar, Rotellar, Fernando, Inogés, Susana, López-Diaz de Cerio, Ascensión, Resano, Leyre, Ponz-Sarvise, Mariano, Rodriguez-Ruiz, Maria E, Chopitea, Ana, Vera, Ruth, Melero, Ignacio

“…Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and…”
Get full text

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better? by Perez-Gracia, Jose Luis, Sanmamed, Miguel F., Melero, Ignacio

Get full text

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy by Perez-Ruiz, Elisabeth, Minute, Luna, Otano, Itziar, Alvarez, Maite, Ochoa, Maria Carmen, Belsue, Virginia, de Andrea, Carlos, Rodriguez-Ruiz, Maria Esperanza, Perez-Gracia, Jose Luis, Marquez-Rodas, Ivan, Llacer, Casilda, Alvarez, Martina, de Luque, Vanesa, Molina, Carmen, Teijeira, Alvaro, Berraondo, Pedro, Melero, Ignacio

“…Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung…”
Get full text

Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients by Sanmamed, Miguel F., Fernández-Landázuri, Sara, Rodríguez, Carmen, Lozano, María D., Echeveste, José I., Pérez Gracia, Jose Luis, Alegre, Estibaliz, Carranza, Omar, Zubiri, Leyre, Martín-Algarra, Salvador, González, Alvaro

“…BRAF V600 mutation has been reported in more than 50% of melanoma cases and its presence predicts clinical activity of BRAF inhibitors (iBRAF). We evaluated…”
Get full text

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation by Alfaro, Carlos, Suárez, Natalia, Martínez-Forero, Ivan, Palazón, Asís, Rouzaut, Ana, Solano, Sarai, Feijoo, Esperanza, Gúrpide, Alfonso, Bolaños, Elixabet, Erro, Lorena, Dubrot, Juan, Hervás-Stubbs, Sandra, Gonzalez, Alvaro, Perez-Gracia, Jose Luis, Melero, Ignacio

“…Interleukin-8 (IL-8, CXCL8) is readily produced by human malignant cells. Dendritic cells (DC) both produce IL-8 and express the IL-8 functional receptors…”
Get full text

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors by Schalper, Kurt A., Carleton, Michael, Zhou, Ming, Chen, Tian, Feng, Ye, Huang, Shu-Pang, Walsh, Alice M., Baxi, Vipul, Pandya, Dimple, Baradet, Timothy, Locke, Darren, Wu, Qiuyan, Reilly, Timothy P., Phillips, Penny, Nagineni, Venkata, Gianino, Nicole, Gu, Jianlei, Zhao, Hongyu, Perez-Gracia, Jose Luis, Sanmamed, Miguel F., Melero, Ignacio

“…Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale…”
Get full text

Comparison of six commercial serum exosome isolation methods suitable for clinical laboratories. Effect in cytokine analysis by Macías, Mónica, Rebmann, Vera, Mateos, Beatriz, Varo, Nerea, Perez-Gracia, Jose Luis, Alegre, Estibaliz, González, Álvaro

“…Background Exosomes are nanovesicles released by cells that can be detected in blood. Exosomes contain several molecules, such as cytokines that have potential…”
Get more information

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer by Fusco, Juan Pablo, Pita, Guillermo, Pajares, María José, Andueza, Maria Pilar, Patiño‐García, Ana, de‐Torres, Juan P., Gurpide, Alfonso, Zulueta, Javier, Alonso, Rosario, Alvarez, Nuria, Pio, Ruben, Melero, Ignacio, Sanmamed, Miguel F., Rodriguez Ruiz, Maria, Gil‐Bazo, Ignacio, Lopez‐Picazo, Jose María, Casanova, Ciro, Baz Davila, Rebeca, Agudo, Antonio, Lozano, Maria Dolores, Gonzalez, Alvaro, Sala, Nuria, Ardanaz, Eva, Benitez, Javier, Montuenga, Luis, Gonzalez‐Neira, Anna, Perez‐Gracia, Jose Luis

“…Single nucleotide polymorphisms (SNPs) may modulate individual susceptibility to carcinogens. We designed a genome‐wide association study to characterize…”
Get full text

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial by Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we…”
Get full text

Circulating melanoma exosomes as diagnostic and prognosis biomarkers by Alegre, Estibaliz, Zubiri, Leyre, Perez-Gracia, Jose Luis, González-Cao, María, Soria, Lourdes, Martín-Algarra, Salvador, González, Alvaro

“…Malignant melanoma is an aggressive cancer with an increasing incidence. Exosomes are actively secreted microvesicles, whose characteristics reflect those of…”
Get full text